Investors + Media

Investor Relations

Corporate Profile

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC(R) protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.


Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
November 5, 2020
– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues ; program updates planned for December 2020 – – Arvinas and Pfizer enter collaboration and supply agreement ; initiation of Phase 1b combination
October 6, 2020
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a keynote

Events + Presentations